Recent Finacing
Recent Raise
HD Immune is a Vienna-based biotechnology company developing a humanized monoclonal antibody therapy C6-17 targeting mutant Huntingtin, with preclinical mtHTT reduction data and acib/BOKU collaborations.
Focus Areas
Recent Investors
Funding round
Investor